Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. World Health Organization, World Health Report, Life in the 21st century. A vision for all. World Health Organisation, 1998, Geneva, Switzerland.

2. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, Schwartsmann G, Tattersall M, Yan S. Essential drugs for cancer therapy: A World Health Organisation consultation. Ann Oncol 1999; 10:385-390.

3. Bonney R. (ed). The Complete Guide to Cancer: 2nd ed. PJB Publications Ltd, Richmond, Surrey, UK, 1998.

4. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351 (Suppl 2):S116-S119.

5. Cimons M. Cancer rates decline as funding increases. Nature Med 1998; 4:544.

6. Food and Drug Administration Web Site. Available at:

7. PhRMA Web Site. Available at

8. Pharmaprojects, PJB Publications, Richmond, 1999.

9. Drews J. Genomic sciences and the medicine of tomorrow. Nature Biotechnol 1996; 14:1516-1518.

10. Goodfellow P. Cited in: Investigational Drugs Weekly Highlights. Current Drugs Ltd, London, UK, 1999;8.

11. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med 1995; 332:1004-1114.

12. Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millenium. Eur J Cancer 1999; 35:2010-2030.

13. Debouck C, Goodfellow PN. DNA microassays in drug discovery and development. Nature Genet 1999; 21:48-51.

14. Anderson WF, Field C, Venter JC. Mammalian gene studies: editorial overview. Curr OpinBiotechnol 1994; 5:577,578.

15. Marshall E. A high-stakes gamble on genome sequencing. Science 1999; 284:1906-1909.

17. Page MJ, Amess B, Rohlff C, Stubberfield C, Parekh R. Proteomics: a major new technology for the drug discovery process. Drug Discovery Today 1999; 4:55-62.

18. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64:235-248.

19. Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998; 351 (Suppl II):1-8.

20. Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell 1994; 78:193-198.

21. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35:531-539.

22. Shayesteh L, Lu Y, Kuo W-L, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PI3KCA is implicated as an oncogene in ovarian cancer. Nature Genet 1999; 21:99-102.

23. Furnari FB, Lin H, Huang H-JS, Cavanee WK. Growth suppression of glioma cells requires a functional phosphatase domain. Proc Natl Acad Sci USA 1997; 94;12,479-12,484.

24. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtros C, Sasaki T, Rutland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumour suppressor gene PTEN. Cell 1998; 95:29-39.

25. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science 1997; 276:1268-1272.

26. Bevan P, Ryder H, Shaw I. Identiftying small-molecule lead compounds: the screening approach to drug discovery. Trends Biotechnol 1995; 13:115-121.

27. Workman P. Towards intelligent anticancer drug screening in the post-genome era? Anti-Cancer Drug Design 1997; 12:525-531.

28. Willett P (ed). Computational methods for the analysis of molecular diversity. In: Perspectives in Drug Design, vols. 7 and 8. Kluwer, Dordrecht, The Netherlands, 1997.

29. Rishton GM. Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 1997; 2:382-384.

30. Blundell TL. Structure-based drug design. Nature 1996; 384 6604(Suppl):23-25.

31. Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discovery Develop 1998; 1(1):4-15.

32. Schreiber S. Visited 5/3/99.

33. Feng S, Kasahara C, Rickles RJ, Schreiber SL. Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands. Proc Natl Acad Sci USA 1995; 92;2,408-12,415.

34. King FD. (ed). Medicinal Chemistry: Principles and Practice. Royal Society of Chemistry, Cambridge, UK, 1994.

35. Terrett NK, Gardner M, Gordon DW, Kobylecki RJ, Steele J. Combinatorial synthesis—the design of compound libraries and the application to drug discovery. Tetrahedron 1995; 51:8135-8173.

36. Hogan JC. Combinatorial chemistry in drug discovery. Nature Biotechnol 1997; 15:328-340.

37. Workman P. Pharmacokinetics and cancer: successes, failures and future prospects. In: Workman P, Graham MA, eds. Pharmacokinetics and Cancer Chemotherapy. Cancer Surveys, vol 17, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1993; 1-26.

38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1996; 23:3-25.

39. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers that are less toxic than misonidazole. Radiation Res 1990; 82:171-190.

40. Workman P, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol 1981; 6:39-49.

41. Rowland M. Pharmacokinetics-QSAR: definitions concepts and models. In: Dearden JC, ed. Quantitative Approaches to Drug Design, Elsevier, Amsterdam, The Netherlands, 1993; 155-161.

42. Mayer JM, van de Waterbeem D. Development of structure-pharmacokinetic relationships. Environ Health Perspect 1985; 61:295-306.

43. Olah TV, McLoughlin DA, Gilbert JD. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom 1997; 11:17-23.

44. Rodrigues AK. Preclinical drug metabolism in the age of high throughput screening: an industrial perspective. Pharmaceutical Res 1997; 14:1504-1515,

45. Hollingshead MG, Alley MC, Camelerier RF, Abbot BJ, Mayo JG, Malspeis L, Grever MR. In vivo cultivation of tumour cells in hollow-fibers. Life Sci 1995; 57:131-141.

46. Gelman KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst 1999; 91: 1281-1287.

47. Weissleder R. Molecular imaging: exploring the next frontier. Radiology 1999; 212:609-614.

48. Burtles SS, Newell DR, Henrar REC, Connors TA. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 1995; 31A:408-410.

49. Burtles SS, Joddrell DI, Newell DR. Evaluation of "rodent only" preclinical toxicology for Phase I trials of new cancer treatments—the Cancer Research Campaign (CRC) experience. Proc Am Assoc Cancer Res 1998; 39:363.

50. Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 1999; 81:760-768.

51. Scrip No. 2374 September 30th, 1998; 20.

52. Levitzki A. Targeting signal transduction for disease therapy. Med Oncol 1997; 14:83-89.

53. Brunton VG, Workman P. Cell-signalling targets for antitumour drug development. Cancer Chemother Pharmacol 1993; 32:1-19.

54. Hunter T. Oncoprotein networks. Cell 1997; 88:333-346.

55. Workman P. The potential for molecular oncology to define new drug targets. In: Kerr DR, Workman P, eds. New Molecular Targets for Cancer Chemotherapy. CRC, Boca Raton, FL, 1994; 1-29.

56. Marshall CJ. Opportunities for pharmacological intervention in the ras pathway. Ann Oncol 1995; 6(Suppl 1):S63-S67.

57. Mulcahy LS, Smith MR, Stacey DW. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 1985; 313:241,242.

58. Stacey DW, Feig LA, Gibbs JB. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol 1991; 11:4053-4064.

59. Leevers SJ, Paterson HF, Marshall CJ. Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane. Nature 1994; 369:411-414.

60. Stokoe D, Macdonald SG, Cadwallader G, et al. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994; 264:1463-1467.

61. Schaap D, Van der Wal J, Howe LR, et al. A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21 (ras). J Biol Chem 1993; 68:20,232-20,236.

62. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH cells. Cell 1994; 77:841-852.

63. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993; 73:381-383.

64. Lui JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, Yang-Yen HF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 1995; 15:3654-3663.

65. Filmus J, Robles A, Shi W, Wong MJ, Colombo LL, Conti CJ. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994; 9:3627-3633.

66. Galactionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target for c-myc. Nature 1996; 382: 511-517.

67. Leone G, DeGregori J, Sears R, Jakoi L, Neving JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387:422-426.

68. Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signalling is required for inactivation of the tumour suppressors pRb cell-cycle control protein. Curr Biol 1997; 7:219-221.

69. Peeper DS, Upton TM, Ladha MH, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386:177-181.

70. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.

71. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 3715:257-261.

72. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988; 195:255-271.

73. Kiaris H, Spandidos DA. Mutations of ras genes in human tumours (review). Int J Oncol 1995; 7: 413-421.

74. Wittinghofer A, Pai EF. The structure of Ras protein: a model for a universal switch. Trends Biochem Sci 1991; 16:382-387.

75. Andreyev JHNA, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90(9):675-684.

76. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-468.

77. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW II, Cordon-Cardo C, Yancopoulos GD, DePinho RA. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400:468-472.

78. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996; 8:197-204.

79. Powis G. Signalling targets for anticancer drug development. Trends Pharm Sci 1991; 12:188-194.

80. Jackson RC. The kinetic properties of switch antimetabolites. J Natl Cancer Inst 1993; 85:539-545.

81. Morrison PF, Dedrick RL. Discovering pharmaceuticals from multistationary biochemical networks. J Natl Cancer Inst 1993; 85:518-519.

82. Bailey JE. Lessons from metabolic engineering for functional genomics and drug discovery. Nature Biotechnol 1999; 17:616-618.

83. Strawn LM, Schawver LK. Tyrosine kinase in disease. Exp Opin Invest Drugs 1998; 7:553-573.

84. Workman P. Towards genomic cancer pharmacology: innovative drugs for the new millenium. Curr Opin Oncol Endo Metab Investig Drugs 2000; 2:21-25.

85. Hall-Jackson CA, Goedert M, Hedge P, Cohen P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 1999; 18:2047-2054.

86. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999; 6:559-568.

87. Sebolt-Leopold JS, Dudley DT, Herrera R, van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 1999; 5(7):810-816.

88. Gray NS, Wodicka L, Thunnissen A-MWH, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim S-H, Lockhart DJ, Schultz PG. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 1998; 281:533-538.

89. Whitesell L, Mimnaugh EG, Decosta B, Myers CE, Neckers LM. Inhibition of heat-shock protein Hsp90-p60(v-Src) heteroprotein complex-formation by benzoquinone ansamycins—essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324-8328.

90. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-oallylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91:1940-1949.

91. Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation:a signalling target for novel anticancer drug design. Anti-Cancer Drug Design 1997; 12:229-238.

92. Sebti S, Hamilton A. Inhibitors of prenyl transferases. Curr Opin Oncol 1997; 9:557-561.

93. Der CJ. American Association of Clinical Oncology Educational Book, 1996; 108-110.

94. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Gip1. Nature 1998; 394:295-299.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment